The minister also added that apart from pandemic and health emergencies, there is an ample scope of collaboration among countries like in the field of vaccine preventable diseases with high morbidity and mortality and for those diseases with no vaccines available currently such as AIDS, TB, etc.
In an application sent to the DCGI on February 9, Srinivas Kosaraju, the head of Quality and Regulatory Affairs of Biological E Limited said the firm had received approval for conducting phase 2/3 clinical study of Corbevax among children and adolescents aged 5-18 years in September.
The court's three liberal justices dissented from the ruling. "When we are wise, we know not to displace the judgments of experts, acting within the sphere Congress marked out and under Presidential control, to deal with emergency conditions," they wrote in the dissenting opinion.
AstraZeneca said this data adds to the growing body of evidence supporting Vaxzevria as a third dose booster, irrespective of the primary vaccination schedules tested.
COVAXIN Booster Dose Data Shows Promising Results
The feature of online appointment for precautionary dose was made operational on the CoWIN portal on Saturday late night. Those eligible to receive precaution dose of Covid vaccines can book online appointment.
The decision came as the Omicron variant is spreading rapidly across the US and has led to record high hospitalisations among younger people.
With the drive starting mostly from schools, many principals and other officials said they received a positive response from students and their families.
The Indian Council of Medical Research also said recently that all Covid vaccines do not prevent infection and are primarily disease-modifying.
WHO Director General issues Strategic Advisory Group of Experts on Immunization’s (SAGE) interim statement on booster doses.
India on Thursday registered 7,495 fresh Covid cases and 434 deaths in a span of 24 hours.
To a query related to Omicron, he said that studies are going on and only after the studies are complete, it will be known which vaccine is how much effective against the new variant.
Meanwhile top US infectious disease expert Anthony Fauci said that early data on the Omicron Covid-19 variant is a "bit encouraging" and does not indicate a great degree of danger, says.
In addition, a significantly higher number of short-lived vaccine reactions were reported in volunteers who received a second dose of Moderna compared to those who received two doses of either AstraZeneca or Pfizer.
The study provides comprehensive data on the real-world vaccine effectiveness and immunological response to vaccination which should help guide policy. The study thus implies that the vaccines continued to be effective in protecting against severe disease and death regardless of the variants.
Justice Chandrachud emphasized, "When you have guidelines, why should the court interfere at this crucial stage of vaccination? Every country in the world has multiple vaccines...look at the developed world, the US."
The Union ministry of health and family welfare said earlier that nearly 100 countries have agreed to the mutual acceptance of vaccination certificates of India's Covid-19 vaccines and the vaccination process.
The research was conducted during the peak of India's second wave of COVID-19 with high test positivity rates for both hospital employees and residents of Delhi, they said.
An analysis reveals that Odisha has very fewer vaccination sites to inoculate its eligible population. Chhattisgarh and Assam have opened 4,300 and 3,489 vaccination sites, respectively, against a mere 2,194 in Odisha
Citing the reasons for booster dose in the US, he said that the Delta variant is causing infections in European countries and that is also a reason for booster dose there. However, India has passed that phase now. "Healthcare workers were the first to be vaccinated. But no case has yet come after around 9 to 10 months which can advocate the need for the booster doses in India", opined Dr Seth.
Meanwhile, a total of 110 countries have recognised India's vaccines, Covishield and Covaxin, and agreed to the mutual recognition of Covid-19 vaccination certificates with India.
He inaugurated the first Global Innovation Summit of the pharmaceuticals sector on Thursday. Union Minister Dr. Mansukh Mandaviya was also present on the occasion.
Noting that India has a large pool of scientists and technologists with a potential to take the industry to greater heights, Modi said this strength needs to be harnessed to discover and make in India .
The Union Health Minister expressed confidence that the country will have vaccinated every Indian by the end of the month-long 'Har Ghar Dastak' campaign, according to the statement.
The phase 3 trial Efficacy and Safety Study involving 25,800 volunteers across 25 sites in India is India's largest ever clinical trial conducted for a Covid-19 vaccine.
Moderna's is of the new class of vaccines that use what is called messenger RNA (mRNA) that cause the body to create some proteins similar to that in the Covid-19 virus and trigger the body's immune system to make antibodies that will fight the coronavirus if it invades the body.
Covaxin uses the same Vero Cell manufacturing platform as other childhood vaccines, including the inactivated polio vaccine.
"The vaccine is one-third the adult dose and the vaccine would be given in two doses, three weeks apart. "
For the study, published in The Lancet journal, the team reviewed data from 7,28,321 individuals aged 12 or above who had received the third dose of the BNT162b2 vaccine.
Hyderabad based Bharat Biotech is expected to submit the data by this weekend.
The top court told the petitioner's counsel that it finds no error with the high court decision in the matter, and it will not entertain the petition.
If authorised, Pfizer-BioNTech vaccine would be the first Covid-19 vaccine for younger children.
Last week, the US drugmaker and its German partner BioNTech, in a study, showed that their mRNA Covid vaccine is safe, well tolerated and produces robust neutralising antibody responses in children aged 5 to 11 years.
On Monday, India said it will resume export of surplus COVID-19 vaccines in the fourth quarter of 2021 under the ''Vaccine Maitri'' programme and to meet its commitment to the COVAX global pool.
Stating that there is no shortage of vaccines in the country, the source said that the Centre is capable of supplying as many vaccine doses the states need, in real-time without any delay.
Earlier, Union Minister for Civil Aviation Jyotiraditya Scindia had launched the first of its kind ‘Medicines from the Sky' project at Vikarabad in Telangana under which drugs and vaccines were to be delivered using drones on September 11.
The countrywide vaccination drive was rolled out on January 16 with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started on February 2.
Moderna is developing vaccines against viral diseases including vaccines against acute respiratory infections, vaccines against persistent infections, as well as vaccines against threats to global public health.
They aim to avoid the use of irregular or suspect products," Anvisa said. The lack of information about the environment at the production bases, combined with the need for vaccine shots to be made in strictly aseptic settings, persuaded officials to take the measure, Anvisa said.
Bhushan also discussed the details of the states and UT's balance stock of 0.5 ml syringes, vaccination coverage among special groups (Transgender Persons, Persons with Disabilities, PWI and Prisoners), Covid vaccination coverage among women particularly pregnant and lactating.